Publication | Closed Access

Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial

Esophageal CancerGastrointestinal OncologyMedicinePaclitaxel Versus PlaceboGastroenterologyPathologyRandomized Phase 3PharmacotherapyCancer TreatmentOncologyRadiation OncologyFrutiga TrialCancer Research